Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Overall results of a randomized trial of the Southwest Oncology Group

Journal of Clinical Oncology

Volumn 20, Issue 8, 2002, Pages 2058-2066

  Sondak, Vernon K ^a   Liu, P Y ^a   Tuthill, Ralph J ^a   Kempf, Raymond A ^a   Unger, Joseph M ^a   Sosman, Jeffrey A ^a   Thompson, John A ^a   Weiss, Geoffrey R ^a   Redman, Bruce G ^a   Jakowatz, James G ^a   Noyes, R Dirk ^a   Flaherty, Lawrence E ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELACINE; TUMOR VACCINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FATIGUE; FEMALE; FEVER; FOLLOW UP; GRANULOMA; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MELANOMA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN ABSCESS; THROMBOCYTOPENIA; VISUAL DISORDER;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; CANCER VACCINES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS;

EID: 0037089687     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.08.071     Document Type: Article

References (21)

1. Vaccine therapy for patients with melanoma
2. Phase III trial of Melacine melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma
3. Tumor-induced suppression of T cells
4. Active specific immunotherapy for melanoma: Phase 1 trial of allogeneic lysates and a novel adjuvant
5. Active specific immunotherapy for melanoma
6. A randomized trial of adjuvant human interferon-γ versus observation in high-risk cutaneous melanoma: A Southwest Oncology Group study
7. SWOG-9035: Adjuvant therapy of intermediate-thickness node-negative melanoma with an allogeneic tumor vaccine
8. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
9. Hemodynamic effects of monophosphoryl lipid A compared to endotoxin
10. A study of the cellular and molecular mediators of the adjuvant action of a nontoxic monophosphoryl lipid A
11. Immunotherapy of cancer: Tumor suppression and regression by cell walls of Mycobacterium phlei attached to oil droplets
12. Effect of DETOX as an adjuvant for melanoma vaccine
13. GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS- 21
14. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
15. Patient preferences for adjuvant interferon alfa- 2b treatment
16. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma
17. Melanoma-specific lysis by cloned CD4+ and CD8+ T cells from actively immunized melanoma patients
18. Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma
19. Association of HLA phenotype with response to active specific immunotherapy of melanoma
20. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: II. Impact of HLA class I antigen expression on outcome
21. The unfulfilled promise of melanoma vaccines